These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26105011)

  • 41. A review of the safety of generic drugs.
    Dighe SV
    Transplant Proc; 1999 May; 31(3A Suppl):23S-24S. PubMed ID: 10330955
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Some thoughts on drug interchangeability.
    Chow SC; Song F; Chen M
    J Biopharm Stat; 2016; 26(1):178-86. PubMed ID: 26366703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulation of Generic Drugs in Japan: the Current Situation and Future Prospects.
    Kuribayashi R; Matsuhama M; Mikami K
    AAPS J; 2015 Sep; 17(5):1312-6. PubMed ID: 25943503
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulatory considerations for generic or biosimilar low molecular weight heparins.
    García-Arieta A; Blázquez A
    Curr Drug Discov Technol; 2012 Jun; 9(2):137-42. PubMed ID: 21838658
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Generic omeprazole delayed-release capsules: in vitro performance evaluations.
    Moore T; Smith A; Ye W; Toler DY; Westenberger BJ; Lionberger R; Raw A; Yu L; Buhse LF
    Drug Dev Ind Pharm; 2009 Aug; 35(8):917-21. PubMed ID: 19555236
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Generic drugs: quality, efficacy, safety and interchangeability].
    Tschabitscher D; Platzer P; Baumgärtel C; Müllner M
    Wien Klin Wochenschr; 2008; 120(3-4):63-9. PubMed ID: 18322766
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Community pharmacists' understanding and perceptions of FDA therapeutic equivalence standards.
    Euen BJ; Fadda HM
    Res Social Adm Pharm; 2019 Jan; 15(1):77-83. PubMed ID: 29567088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
    Kefalas CH; Ciociola AA
    Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
    [No Abstract]   [Full Text] [Related]  

  • 51. Generic drugs and the prescribing physician.
    Nightingale SL; Morrison JC
    JAMA; 1987 Sep; 258(9):1200-4. PubMed ID: 3626003
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.
    Bialer M; Midha KK
    Epilepsia; 2010 Jun; 51(6):941-50. PubMed ID: 20384761
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan.
    Kuribayashi R; Takishita T; Mikami K
    J Pharm Sci; 2016 Aug; 105(8):2270-7. PubMed ID: 27372551
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The identity problem.
    Nat Biotechnol; 2010 Sep; 28(9):877. PubMed ID: 20829806
    [No Abstract]   [Full Text] [Related]  

  • 55. Issues in the use of generic antiarrhythmic drugs.
    Reiffel JA
    Curr Opin Cardiol; 2001 Jan; 16(1):23-9. PubMed ID: 11124715
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brand and generic medications: are they interchangeable?
    Al-Jazairi AS; Bhareth S; Eqtefan IS; Al-Suwayeh SA
    Ann Saudi Med; 2008; 28(1):33-41. PubMed ID: 18299655
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-World Data Approaches for Early Detection of Potential Safety and Effectiveness Signals for Generic Substitution: A Metoprolol Extended-Release Case Study.
    Brown JD; Henriksen C; Vozmediano V; Schmidt S
    J Clin Pharmacol; 2019 Sep; 59(9):1275-1284. PubMed ID: 31087552
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The clinical and economic impact of generic drugs in the treatment of epilepsy].
    Argumosa A; Herranz JL
    Rev Neurol; 2005 Jul 1-15; 41(1):45-9. PubMed ID: 15999330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations.
    Knoben JE; Scott GR; Tonelli RJ
    Am J Hosp Pharm; 1990 Dec; 47(12):2696-700. PubMed ID: 2278285
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
    Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
    J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.